Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9469.026 | 0.9650 | 0.9418 | 1.2092 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9469.026 | 0.9789 | 0.9650 | 1.2092 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9469.026 | 1.0242 | 1.0400 | 1.2092 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9469.026 | 0.9869 | 0.9783 | 1.2092 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9469.026 | 1.0212 | 1.0350 | 1.2092 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9469.026 | 0.9923 | 0.9872 | 1.2092 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9469.026 | 0.9795 | 0.9659 | 1.2092 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 7.2 | uM | 9469.026 | 0.9029 | 0.8380 | 1.2092 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 10268.122 | 0.8929 | 0.6731 | 0.6345 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 10268.122 | 1.4860 | 2.7334 | 0.6345 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 10268.122 | 1.1585 | 1.5219 | 0.6345 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 10268.122 | 1.2792 | 1.9481 | 0.6345 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 10268.122 | 1.1077 | 1.3500 | 0.6345 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 10268.122 | 1.6516 | 3.4100 | 0.6345 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 0.288 | uM | 10268.122 | 1.0361 | 1.1148 | 0.6345 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 1.44 | uM | 10268.122 | 0.9504 | 0.8458 | 0.6345 | |
| HCC38 | TNBC | Basal B | Trastuzumab | HER2 | ErbB | 7.2 | uM | 10268.122 | 0.8284 | 0.4865 | 0.6345 | |
| HCC70 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0000184 | uM | 9501.026 | 0.9470 | 0.8619 | 0.7616 | |
| HCC70 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0000922 | uM | 9501.026 | 1.0559 | 1.1480 | 0.7616 | |
| HCC70 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.000461 | uM | 9501.026 | 1.0230 | 1.0605 | 0.7616 | |
| HCC70 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0023 | uM | 9501.026 | 1.0032 | 1.0085 | 0.7616 | |
| HCC70 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0115 | uM | 9501.026 | 0.9331 | 0.8261 | 0.7616 | |
| HCC70 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.0576 | uM | 9501.026 | 0.9477 | 0.8637 | 0.7616 | |
| HCC70 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 0.288 | uM | 9501.026 | 1.0287 | 1.0756 | 0.7616 | |
| HCC70 | TNBC | Basal A | Trastuzumab | HER2 | ErbB | 1.44 | uM | 9501.026 | 1.0871 | 1.2318 | 0.7616 |